Sagimet Biosciences, Inc. Class A's total assets for Q4 2025 were $116.48M, a decrease of -9.28% from the previous quarter. SGMT total liabilities were $5.10M for the fiscal quarter, a -44.23% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.